The Shifting Landscape of Lupus Nephritis Management: A Review

被引:3
作者
Bankole, Adegbenga A. [1 ]
Nwaonu, Jane N. [1 ]
机构
[1] Virginia Tech Carilion Sch Med, Rheumatol, Roanoke, VA 24016 USA
关键词
systemic lupus erythematosus; lupus nephritis; lipid disorders; immune; acute tubulointerstitial nephritis; kidney disease; immune mediated side effects; anti-nuclear antibody; auto immune; systemic reviews; RENAL-VEIN THROMBOSIS; NEPHROTIC SYNDROME MECHANISMS; MYCOPHENOLATE-MOFETIL; ANTI-C1Q ANTIBODIES; DISEASE ACTIVITY; ERYTHEMATOSUS; THERAPY; RISK; CLASSIFICATION; NEPHROPATHY;
D O I
10.7759/cureus.20950
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Systemic lupus erythematosus (SLE) is commonly the first autoimmune disease that comes to mind for most people when rheumatology is mentioned. It remains an enigma that many of us, including patients and healthcare providers, do not fully understand. Although an ancient disease, it still remains difficult to both diagnose and treat. Historically, there has always been a paucity of therapeutic interventions for SLE as a whole. One of the most distressing manifestations for the patient and diagnostic and therapeutically challenging aspects of SLE is lupus nephritis (LN). There has historically been some difficultly in the development of LN drugs that provide significant therapeutic benefits while having an acceptable side-effect profile. This difficulty led to decades in which no drugs were approved for LN. With a better understanding of the pathogenesis of SLE and LN and improvement in trial design, great therapeutic strides have recently been made. The immunosuppressive landscape of LN has changed recently with the approval of two newer agents as well as a number of promising trials in LN. With the increased number of therapeutic agents (both immunosuppressive and non-immunosuppressive), the clinical question is how and when to use these medications, and, more importantly, which agents to use first. With the increased number of agents, the answers to these questions are becoming more difficult to answer. The purpose of the paper is to review updates in LN diagnosis and management.
引用
收藏
页数:8
相关论文
共 73 条
[1]   Therapy with statins in patients with refractory rheumatic diseases:: a preliminary study [J].
Abud-Mendoza, C ;
de la Fuente, H ;
Cuevas-Orta, E ;
Baranda, L ;
Cruz-Rizo, J ;
González-Amaro, R .
LUPUS, 2003, 12 (08) :607-611
[2]  
Agrawal S, 2018, NAT REV NEPHROL, V14, P57, DOI 10.1038/nrneph.2017.155
[3]   Strategy for second kidney biopsy in patients with lupus nephritis [J].
Alsuwaida, Abdulkareem ;
Husain, Sufia ;
Alghonaim, Mohammed ;
AlOudah, Noura ;
Alwakeel, Jamal ;
Ullah, Anhar ;
Kfoury, Hala .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (04) :1472-1478
[4]  
Alvarez-Castells A, 2001, Arch Esp Urol, V54, P603
[5]   Individualizing Therapy in Lupus Nephritis [J].
An, Yu ;
Zhang, Haitao ;
Liu, Zhihong .
KIDNEY INTERNATIONAL REPORTS, 2019, 4 (10) :1366-1372
[6]   RENAL-VEIN THROMBOSIS, NEPHROTIC SYNDROME, AND SYSTEMIC LUPUS-ERYTHEMATOSUS - ASSOCIATION IN 4 CASES [J].
APPEL, GB ;
WILLIAMS, GS ;
MELTZER, JI ;
PIRANI, CL .
ANNALS OF INTERNAL MEDICINE, 1976, 85 (03) :310-317
[7]   RENAL INVOLVEMENT IN SYSTEMIC LUPUS-ERYTHEMATOSUS (SLE) - STUDY OF 56 PATIENTS EMPHASIZING HISTOLOGIC CLASSIFICATION [J].
APPEL, GB ;
SILVA, FG ;
PIRANI, CL ;
MELTZER, JI ;
ESTES, D .
MEDICINE, 1978, 57 (05) :371-410
[8]   Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices [J].
Bajema, Ingeborg M. ;
Wilhelmus, Suzanne ;
Alpers, Charles E. ;
Bruijn, Jan A. ;
Colvin, Robert B. ;
Cook, H. Terence ;
D'Agati, Vivette D. ;
Ferrario, Franco ;
Haas, Mark ;
Jennette, J. Charles ;
Joh, Kensuke ;
Nast, Cynthia C. ;
Noel, Laure-Helene ;
Rijnink, Emilie C. ;
Roberts, Ian S. D. ;
Seshan, Surya V. ;
Sethi, Sanjeev ;
Fogo, Agnes B. .
KIDNEY INTERNATIONAL, 2018, 93 (04) :789-796
[9]   Differential effects of calcium antagonist subclasses on markers of nephropathy progression [J].
Bakris, GL ;
Weir, MR ;
Secic, M ;
Campbell, B ;
Weis-McNulty, A .
KIDNEY INTERNATIONAL, 2004, 65 (06) :1991-2002
[10]   PULSE METHYLPREDNISOLONE THERAPY IN DIFFUSE PROLIFERATIVE LUPUS NEPHRITIS [J].
BARRON, KS ;
PERSON, DA ;
BREWER, EJ ;
BEALE, MG ;
ROBSON, AM .
JOURNAL OF PEDIATRICS, 1982, 101 (01) :137-141